Disruptions, Vulnerabilities and Resilience Strategies in the Pharmaceutical Supply Chain
This study seeks to examine why the pharmaceutical supply chain in the UK is susceptible to the impact of disruptions and how resilience strategies can be used to mitigate the impact of these disruptions
Your Field of Practice: Please tick the response most suitable to you *
Years of Experience in the Pharmaceutical Supply chain *
In your experience what is the most common form of disruptive activity to your supply chain? *
In your opinion, when should information about disruptive activity in the supply chain be shared with you? *
Following an initial alert, when should updates about disruptive activity be provided to you? *
Your answer
We feel the impact of disruptive activities because: *
Strongly agree
Somewhat agree
Neither agree nor disagree
Somewhat disagree
Strongly disagree
I don't know
Not applicable
Our business supply chain partners do not exchange relevant and/or timely information
Our supply chain partners do not consider how their actions will affect us
We do not trust our supply chain partners
We do not have confidence in our supply chain partners actions
Our supply chain partners prevent us from doing what we want to do
We do not agree with supply chain partners on critical issues like the distribution of our products
Generally, we are not satisfied with our overall relationship with our supply chain partner
There is no transparency in the pricing of goods within the supply chain
Information regarding product prices is readily available within our supply chain.
Our operations and products are subject to stringent government regulations.
We are uncertain about economic and /or political issues
Our firm does not understand the market demand
Our supply chain partners do not understand the market demand
Production of our products is very complex
Our products require strict storage or handling controls to maintain their purity and/or integrity that may cause delay
We are part of a global distribution network
Our supply chain partners encounter significant disruptions frequently
We depend on the use of regulated or restricted materials
Regulation on pricing and reimbursement complicates transactions
The impact of disruption on the supply chain will be reduced if: *
Strongly agree
Somewhat agree
Neither agree nor disagree
Somewhat disagree
Strongly disagree
I don't know
Not apllicable
The demand for our product is stable
There is access to alternative supply chain partners
There is access to alternative products
The lead times for manufacturing of our products are shorter
We have access to tracking information throughout the supply chain
We have access to tracking materials throughout the supply chain
We have joint decisions with our supply chain partners when working out solutions
We share resources internally
We share resources with our supply chain partners
Our supply chain partners share their resources with us
Joint employee training with other supply chain partners
There is a feeling of fairness with our supply chain partners
In your opinion what other issues are necessary to consider when dealing with disruptions in the pharmaceutical supply chain?
Your answer
Submit
Never submit passwords through Google Forms.
This content is neither created nor endorsed by Google. Report Abuse - Terms of Service